Valsartan, Losartan, and Irbesartan Products Liability Litigation
The causation theory is supported by scientific evidence indicating that NDMA and N-nitrosoirbesartan, contaminants found in Valsartan, Losartan, and Irbesartan, are probable human carcinogens. These nitrosamines can cause DNA mutations leading to cancers such as liver, kidney, and other malignancies. Regulatory agencies like the FDA have confirmed the presence of these impurities and their carcinogenic potential based on animal studies and limited human data, which underpin the legal claims linking drug contamination to increased cancer risk.
1,418
Pending actions
1,629
Total actions filed
Active
Status
02/14/2019
Established
Filing deadline
The court schedules, including the amended wave 2 bellwether schedule, set deadlines for filings and discovery through late 2025, with key dates such as the final pretrial order due by November 24, 2025. Specific statutes of limitations are not fixed at the federal level but generally follow New Jersey's two-year limit from injury or discovery, as confirmed by legal sources.
Who qualifies
Plaintiffs must have used Valsartan, Losartan, or Irbesartan contaminated with nitrosamines such as NDMA or NDEA, with exposure duration and dosage details documented in court filings. They must have been diagnosed with a cancer or related condition after exposure, with the injury onset within a period consistent with the latency of cancer development, typically several years post-exposure. Medical documentation confirming diagnosis and exposure details is required.
Products involved
- Valsartan (Diovan, Diovan HCT, generic)
- Losartan (Cozaar, generic)
- Irbesartan (Avapro, generic)
Alleged injuries
- Liver cancer
- Kidney cancer
- Other malignancies linked to NDMA and N-nitrosoirbesartan contamination
Bellwether trials
The first bellwether trial in MDL-2875 was dismissed in November 2025, with no new trials scheduled or conducted since then. Six bellwether cases had been selected by October 2024, but there are no recent updates or verdicts reported, indicating possible delays or procedural uncertainties.
Settlement landscape
Settlement estimates for Valsartan cases range from $100,000 to over $400,000 per case, with recent court filings indicating that the litigation is nearing final settlement approval. Court orders from early 2026 suggest that settlement processes are in advanced stages, with preliminary approvals granted for multiple class actions and individual claims.
Lead counsel
- Ruben Honik from Golomb & Honik, P.C.
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
